Successful pharmaceutical‐grade streptozotocin (STZ)‐induced hyperglycemia in a conscious tethered baboon (Papio hamadryas) model

Non‐human primate (NHP) diabetic models using chemical ablation of β‐cells with STZ have been achieved by several research groups. Chemotherapeutic STZ could lead to serious adverse events including nephrotoxicity, hepatotoxicity, and mortality.

[1]  L. Orci,et al.  Studies of the Diabetogenic Action of Streptozotocin.∗ , 1967, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[2]  V. Devita,et al.  Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998) , 1974, Cancer.

[3]  D. Hearse,et al.  The synthesis of [14C] streptozotocin and its distribution and excretion in the rat. , 1974, The Biochemical journal.

[4]  A. Lundin,et al.  Treatment of malignant metastatic pancreatic insulinoma with streptozotocin. Review of 21 cases described in detail in the literature and report of complete remission of a new case. , 2009, Acta medica Scandinavica.

[5]  H. Feiner,et al.  Nephrotoxicity of nitrosoureas , 1981, Cancer.

[6]  Gupta Ra,et al.  Dose dependent alteration in lipid and carbohydrate metabolites in streptozotocin induced diabetic rats. , 1982 .

[7]  V. Dixit,et al.  Dose dependent alteration in lipid and carbohydrate metabolites in streptozotocin induced diabetic rats. , 1982, Endokrinologie.

[8]  Y. Olsson,et al.  Hypoglycemic Brain Injury in the Rat: Correlation of Density of Brain Damage with the EEG Isoelectric Time: A Quantitative Study , 1984, Diabetes.

[9]  O. Jonasson,et al.  Biochemical changes in rhesus monkey during the first days after streptozotocin administration are indicative of selective beta cell destruction. , 1988, Metabolism: clinical and experimental.

[10]  Coelho Am,et al.  A social tethering system for nonhuman primates used in laboratory research. , 1990 .

[11]  K. Carey,et al.  A social tethering system for nonhuman primates used in laboratory research. , 1990, Laboratory animal science.

[12]  G. Kootstra,et al.  Diabetes induction and pancreatic transplantation in the cynomolgus monkey: methodological considerations , 1991, Transplant international : official journal of the European Society for Organ Transplantation.

[13]  P. Cryer,et al.  Reduced Neuroendocrine and Symptomatic Responses to Subsequent Hypoglycemia After 1 Episode of Hypoglycemia in Nondiabetic Humans , 1991, Diabetes.

[14]  M. Field,et al.  TOTAL PANCREATECTOMY IN THE PIG FOR ISLET TRANSPLANTATION TECHNICAL ALTERNATIVES , 1991, Transplantation.

[15]  E. Morrison,et al.  Streptozotocin alters pancreatic beta-cell responsiveness to glucose within six hours of injection into rats. , 1996, The West Indian medical journal.

[16]  Y. Matsuzawa,et al.  Demonstration of Two Different Processes of β-Cell Regeneration in a New Diabetic Mouse Model Induced by Selective Perfusion of Alloxan , 1997, Diabetes.

[17]  M. Talamini,et al.  Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. , 1997, Annals of surgery.

[18]  G. Szot,et al.  Induction, maintenance, and reversal of streptozotocin-induced insulin-dependent diabetes mellitus in the juvenile cynomolgus monkey (Macaca fascilularis). , 1999, Transplantation.

[19]  Y. Matsuzawa,et al.  A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. , 2000, The New England journal of medicine.

[20]  I. Barshack,et al.  Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia , 2000, Nature Medicine.

[21]  R. Bontrop,et al.  Non‐human primates: essential partners in biomedical research , 2001, Immunological reviews.

[22]  M. Vranic,et al.  Low-dose IGF-I has no selective advantage over insulin in regulating glucose metabolism in hyperglycemic depancreatized dogs. , 2001, The Journal of endocrinology.

[23]  R. Brentjens,et al.  Islet cell tumors of the pancreas: the medical oncologist's perspective. , 2001, The Surgical clinics of North America.

[24]  M. Fujimiya,et al.  NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice , 2003, Nature Medicine.

[25]  Lisa J. Martin,et al.  The baboon as a nonhuman primate model for the study of the genetics of obesity. , 2003, Obesity research.

[26]  H. Auchincloss,et al.  The Effect of Low Versus High Dose of Streptozotocin in Cynomolgus Monkeys (Macaca Fascilularis) , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  D. Harlan,et al.  Induction of diabetes in nonhuman primates by means of temporary arterial embolization and selective arterial injection of streptozotocin. , 2004, Radiology.

[28]  S. Bonner-Weir,et al.  New sources of pancreatic β-cells , 2005, Nature Biotechnology.

[29]  Todd B. Brown,et al.  Procedural sedation in the acute care setting. , 2005, American family physician.

[30]  H. Kaneto,et al.  PDX-1/VP16 fusion protein, together with NeuroD or Ngn3, markedly induces insulin gene transcription and ameliorates glucose tolerance. , 2005, Diabetes.

[31]  M. Haskins,et al.  Large animal models and gene therapy , 2006, European Journal of Human Genetics.

[32]  M. Koulmanda.  Islet transplant model in nonhuman primates: use of streptozotocin , 2006 .

[33]  A. Imagawa,et al.  Pathogenesis of fulminant type 1 diabetes. , 2006, The review of diabetic studies : RDS.

[34]  S. Schapiro,et al.  Non-human Primates in Biomedical Research , 2006 .

[35]  P. Adamson,et al.  Understanding and managing methotrexate nephrotoxicity. , 2006, The oncologist.

[36]  R. Bottino,et al.  Induction of Diabetes in Cynomolgus Monkeys With High-dose Streptozotocin: Adverse Effects and Early Responses , 2006, Pancreas.

[37]  P. Carlen,et al.  Hypoglycemic seizures during transient hypoglycemia exacerbate hippocampal dysfunction , 2007, Neurobiology of Disease.

[38]  P. Butler,et al.  The replication of β cells in normal physiology, in disease and for therapy , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[39]  S. Lenzen,et al.  The mechanisms of alloxan- and streptozotocin-induced diabetes , 2008, Diabetologia.

[40]  M. Kay,et al.  Adenovirus transduction is required for the correction of diabetes using Pdx-1 or Neurogenin-3 in the liver. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  J. Gromada,et al.  Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. , 2007, Endocrine reviews.

[42]  R. DeFronzo,et al.  Physiological and Molecular Determinants of Insulin Action in the Baboon , 2008, Diabetes.

[43]  J. Meier,et al.  Beta cell mass in diabetes: a realistic therapeutic target? , 2008, Diabetologia.

[44]  Tamara B. Harris,et al.  Diabetes-related complications, glycemic control, and falls in older adults , 2008 .

[45]  L. Velíšek,et al.  Metabolic Environment in Substantia Nigra Reticulata Is Critical for the Expression and Control of Hypoglycemia-Induced Seizures , 2008, The Journal of Neuroscience.

[46]  Hugo A Katus,et al.  Ultrasound targeted microbubble destruction for drug and gene delivery. , 2008, Expert opinion on drug delivery.

[47]  C. Patterson,et al.  Acute Complications and Drug Misuse Are Important Causes of Death for Children and Young Adults With Type 1 Diabetes , 2008, Diabetes Care.

[48]  D. Cooper,et al.  Chapter 4: Pre‐clinical efficacy and complication data required to justify a clinical trial , 2009, Xenotransplantation.

[49]  P. Cryer,et al.  Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. , 2009, The Journal of clinical endocrinology and metabolism.

[50]  S. Tardif,et al.  The Baboon in Biomedical Research , 2009 .

[51]  R. Robertson,et al.  Islet Transplantation a Decade Later and Strategies for Filling a Half-Full Glass , 2010, Diabetes.

[52]  R. Sherwin,et al.  Hypoglycemia in Type 1 Diabetes , 2010, Diabetes.

[53]  J. Oh,et al.  Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus , 2010, The Journal of pharmacy and pharmacology.

[54]  M. Perazella,et al.  Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. , 2010, Seminars in nephrology.

[55]  J. Munson,et al.  Refining the high-dose streptozotocin-induced diabetic non-human primate model: an evaluation of risk factors and outcomes , 2011, Experimental biology and medicine.

[56]  J. Markmann,et al.  Induction of diabetes with signs of autoimmunity in primates by the injection of multiple-low-dose streptozotocin. , 2011, Biochemical and biophysical research communications.

[57]  C. Cook,et al.  Update on inpatient glycemic control in hospitals in the United States. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[58]  Sirong He,et al.  Treatment and risk factor analysis of hypoglycemia in diabetic rhesus monkeys , 2011, Experimental biology and medicine.

[59]  Protocol for the measurement of fatty acid and glycerol turnover in vivo in baboons[S] , 2011, Journal of Lipid Research.

[60]  A. Imagawa,et al.  Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute‐onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012) , 2012, Journal of diabetes investigation.

[61]  J. Munson,et al.  Successful implementation of cooperative handling eliminates the need for restraint in a complex non‐human primate disease model , 2012, Journal of medical primatology.

[62]  A. Cherrington,et al.  Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. , 2012, The Journal of clinical investigation.

[63]  Aileen J F King,et al.  The use of animal models in diabetes research , 2012, British journal of pharmacology.

[64]  J. Munson,et al.  Management of adverse side-effects after chemotherapy in macaques as exemplified by streptozotocin: case studies and recommendations , 2012, Laboratory animals.

[65]  D. Nicolella,et al.  Baboons as a model to study genetics and epigenetics of human disease. , 2013, ILAR journal.

[66]  L. Hazrati,et al.  Severe Hypoglycemia in a Juvenile Diabetic Rat Model: Presence and Severity of Seizures Are Associated with Mortality , 2013, PloS one.

[67]  D. Daphna-Iken,et al.  Severe Hypoglycemia–Induced Lethal Cardiac Arrhythmias Are Mediated by Sympathoadrenal Activation , 2013, Diabetes.

[68]  R. DeFronzo,et al.  Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1 , 2014, Cell cycle.

[69]  S. Klein,et al.  Absence of leptin triggers type 1 diabetes , 2014, Nature Medicine.

[70]  A. Kirk,et al.  First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes—Chapter 4: pre‐clinical efficacy and complication data required to justify a clinical trial , 2016, Xenotransplantation.